15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Phathom Pharmaceuticals Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $14.00 to $26.00, a moderate spread. The average target of $21.00 sits 123% above the current $9.42. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.11 next quarter toward $1.11 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Phathom Pharmaceuticals Inc.
As of Sep, 4 of 4 firms rate PHAT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PHAT EPS & revenue forecast
EPS · NEXT QUARTER
$0.11
Range $0.07 – $0.15 · 4 analysts · -239% YoY
Next period, 4 analysts expect Phathom Pharmaceuticals Inc to earn $0.11 a share (range $0.07 – $0.15), versus $-0.08 a year earlier. Full-year consensus is $-0.03, growing to $1.11 the year after.
REVENUE · NEXT QUARTER
$98.6M
Range $95.7M – $102.5M · 4 analysts · +71% YoY
Revenue is expected to reach $98.6M (range $95.7M – $102.5M), +71.1% year-over-year. Full-year consensus is $316.6M, rising to $494.3M next year.
Top analysts covering Phathom Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PHAT.
#1
Chase Knickerbocker
Craig-Hallum · Rank #19
Buy
No targeton PHAT
Overall win rate
61%
+ Follow
#2
Yatin Suneja
Guggenheim · Rank #21
Buy
$22.00+133.5% to target
Overall win rate
53%
+ Follow
#3
MC
Matthew Caufield
HC Wainwright & Co. · Rank #92
Buy
$26.00+176.0% to target
Overall win rate
54%
+ Follow
#4
Kristen Kluska
Cantor Fitzgerald · Rank #169
Buy
$29.00+207.9% to target
Overall win rate
38%
+ Follow
#5
Joseph Stringer
Needham · Rank #195
Buy
$22.00+133.5% to target
Overall win rate
36%
+ Follow
PHAT stock forecast FAQ
What is PHAT's average 12-month price target?+
The 4 analysts with a live target average $21.00 for Phathom Pharmaceuticals Inc over the next 12 months, ranging from a $26.00 high to a $14.00 low.
Is PHAT stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PHAT?+
The Street-high target is $26.00 (HC Wainwright & Co.), and the Street-low is $14.00 (Barclays). The average of all 4 active targets is $21.00.
How many Wall Street analysts cover PHAT?+
4 analysts have an active rating on Phathom Pharmaceuticals Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering PHAT?+
Among analysts who currently cover PHAT, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #19). Their current call is Buy.
What is Phathom Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.11 per share (range $0.07 – $0.15) across 4 analysts. Full-year EPS is projected at $-0.03, rising to $1.11 the following year.
How much revenue is Phathom Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $98.6M (range $95.7M – $102.5M). Full-year revenue is projected at $316.6M, growing to $494.3M next year.
Have analysts been upgrading or downgrading PHAT lately?+
As of Sep, 4 of 4 firms rate PHAT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PHAT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
